Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Abstract:
Quintessence today announced that data for their lead EVade™ Ribonuclease, called QBI-139, will be presented at the American Society of Clinical Oncology 46th Annual Meeting.

Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Madison, WI | Posted on June 7th, 2010

QBI-139 is a protein therapeutic that targets the RNA in cancer cells. The data from abstract TPS162 will be presented at 8 AM on Monday June 7, 2010. The focus will be on the design of the Phase I clinical trial of QBI-139. QBI-139 has shown broad single agent activity against a variety of cancer models addressing significant unmet need, such as non-small cell lung and pancreatic cancers.

####

About Quintessence Biosciences
Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of cancer therapies based on the proprietary EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is in a Phase 1 clinical trial at The University of Texas M.D. Anderson Cancer Center and The University of Wisconsin Carbone Cancer Center. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About the American Society of Clinical Oncology
The 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) is being held in Chicago, June 4-8, 2010. This year's Annual Meeting will focus on Advancing Quality through Innovation. More than 30,000 cancer specialists from around the world will gather to discuss the latest innovations in research, quality, practice and technology in cancer. For more information, visit chicago2010.asco.org/Home.aspx

About the ASCO Annual Meeting Trials in Progress Poster Session
The objective of the Trials in Progress Poster Session is to publicize ongoing phase I or phase II trials and stimulate discussion and participation among peers. The posters discuss the science behind the trial, including pre-clinical data. In addition, the posters will describe the trial design and current enrollment status.

For more information, please click here

Contacts:
Dr. Laura Strong
President and Chief Operating Officer
608-441-2950


Copyright © Quintessence Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanostructures Increase Corrosion Resistance in Metallic Body Implants May 24th, 2015

Iranian Scientists Use Magnetic Field to Transfer Anticancer Drug to Tumor Tissue May 24th, 2015

Basel physicists develop efficient method of signal transmission from nanocomponents May 23rd, 2015

This Slinky lookalike 'hyperlens' helps us see tiny objects: The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists' ability to observe single molecules May 23rd, 2015

Nanomedicine

Nanostructures Increase Corrosion Resistance in Metallic Body Implants May 24th, 2015

Iranian Scientists Use Magnetic Field to Transfer Anticancer Drug to Tumor Tissue May 24th, 2015

New Antibacterial Wound Dressing in Iran Can Display Replacement Time May 22nd, 2015

Researchers develop new way to manufacture nanofibers May 21st, 2015

Announcements

Nanostructures Increase Corrosion Resistance in Metallic Body Implants May 24th, 2015

Iranian Scientists Use Magnetic Field to Transfer Anticancer Drug to Tumor Tissue May 24th, 2015

Basel physicists develop efficient method of signal transmission from nanocomponents May 23rd, 2015

This Slinky lookalike 'hyperlens' helps us see tiny objects: The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists' ability to observe single molecules May 23rd, 2015

Events/Classes

Haydale Named Lead Sponsor for Cambridge Graphene Festival May 22nd, 2015

Aspen Aerogels to Present at the Cowen and Company Technology, Media & Telecom Conference May 21st, 2015

Directa Plus in Barcelona to present the innovative project GEnIuS for oil spills clean-up activities: The company has created a graphene-based product for the remediation of water contaminated by oil and hydrocarbons May 21st, 2015

Nanometrics Announces Live Webcast of Upcoming Investor and Analyst Day May 20th, 2015

Nanobiotechnology

This Slinky lookalike 'hyperlens' helps us see tiny objects: The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists' ability to observe single molecules May 23rd, 2015

Supercomputer unlocks secrets of plant cells to pave the way for more resilient crops: IBM partners with University of Melbourne and UQ May 21st, 2015

Researchers develop new way to manufacture nanofibers May 21st, 2015

Nature inspires first artificial molecular pump: Simple design mimics pumping mechanism of life-sustaining proteins found in living cells May 19th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project